109 related articles for article (PubMed ID: 7963890)
1. [The importance of CA125 immunohistochemical staining in patients with ovarian cancer].
Adachi S; Noda T; Kiyozuka Y; Ito K; Itani Y; Tsujimoto A; Sakakura S; Yoshida T; Umekage H; Nakayama M
Nihon Sanka Fujinka Gakkai Zasshi; 1994 Sep; 46(9):896-902. PubMed ID: 7963890
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
4. Ovarian vein vs peripheral blood CA125 serum levels: a comparative study.
Podnos YD; Gamboa G; Kurosaki T; Buller R; Walker JL; Manetta A
Gynecol Oncol; 1997 Jul; 66(1):71-4. PubMed ID: 9234924
[TBL] [Abstract][Full Text] [Related]
5. Immunohistological analysis of stress-induced phosphoprotein 1 in ovarian cancer patients with low serum cancer antigen 125 levels.
Chao A; Lee LY; Hsueh C; Lin CY; Tsai CL; Chao AS; Lin CT; Chou HH; Chang TC; Wang TH
Taiwan J Obstet Gynecol; 2013 Jun; 52(2):185-91. PubMed ID: 23915849
[TBL] [Abstract][Full Text] [Related]
6. Retrospective evaluation of tumor markers in ovarian mature cystic teratoma and ovarian endometrioma.
Kataoka T; Watanabe Y; Hoshiai H
J Obstet Gynaecol Res; 2012 Aug; 38(8):1071-6. PubMed ID: 22568880
[TBL] [Abstract][Full Text] [Related]
7. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of CA125, CA19-9, and Ki-67 in stage III or IV endometriosis: positive correlation between serum CA125 level and endometriotic epithelial cell proliferation.
Toki T; Kubota J; Lu X; Nakayama K
Acta Obstet Gynecol Scand; 2000 Sep; 79(9):771-6. PubMed ID: 10993101
[TBL] [Abstract][Full Text] [Related]
9. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic value of multiple tumor marker detection for mature and immature teratoma of the ovary].
Chen C; Li JD; Huang H; Feng YL; Wang LH; Chen L
Ai Zheng; 2008 Jan; 27(1):92-5. PubMed ID: 18184473
[TBL] [Abstract][Full Text] [Related]
11. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
12. Pre-operative prediction of serum CA125 level in women with ovarian masses.
Benjapibal M; Neungton C
J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
[TBL] [Abstract][Full Text] [Related]
13. Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic?
Sparholt MH; Høgdall CK; Nedergaard L; Heeran MC; Christensen IJ; Høgdall EV
APMIS; 2013 Jan; 121(1):38-44. PubMed ID: 23030299
[TBL] [Abstract][Full Text] [Related]
14. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
Wu L; Sun J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
16. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
17. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
Shi W; Zhang YJ; Jiang CY
Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
[TBL] [Abstract][Full Text] [Related]
18. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
[TBL] [Abstract][Full Text] [Related]
19. Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage.
Fures R; Buković D; Hodek B; Klarić B; Herman R; Grubisić G
Coll Antropol; 1999 Jun; 23(1):189-94. PubMed ID: 10402722
[TBL] [Abstract][Full Text] [Related]
20. IMMULITE OM-MA assay: a useful diagnostic tool in patients with benign and malignant ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2535-6. PubMed ID: 10470190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]